Evidence for the activation of complement via the alternate pathway in skin diseases. II. Dermatitis herpetiformis.
D000328:Adult; D000368:Aged; D000818:Animals; D001706:Biopsy; D003165:Complement System Proteins / Q000378:metabolism*; D003622:Dapsone / Q000627:therapeutic use; D003874:Dermatitis Herpetiformis / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D005455:Fluorescent Antibody Technique; D006736:Horses / Q000276:immunology; D006801:Humans; D007106:Immune Sera; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007419:Intestinal Secretions / Q000276:immunology; D007583:Jejunum; D008297:Male; D008875:Middle Aged; D011414:Properdin; D011817:Rabbits / Q000276:immunology; D012867:Skin / Q000473:pathology
D007106:Immune Sera; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011414:Properdin; D003622:Dapsone; D003165:Complement System Proteins